Streetbeat News

Products Services

LDOS

Leidos has entered into a strategic collaboration with Permion to accelerate the use of AI in critical national security mission sets. This partnership is expected to enhance Leidos' capabilities in AI and machine learning, potentially leading to new contracts and increased revenues.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:01 pm

BYND

Beyond Meat's executive stated that despite initial promise, their programs did not scale well at retail and failed to increase new category users as desired.

Portfolio Pulse from Charles Gross

August 07, 2023 | 9:34 pm

ATVI

MSFT

TSLA

Tesla CEO Elon Musk praised Diablo IV, a video game title from Activision Blizzard Inc (NASDAQ:ATVI), which saw huge sales figures. Diablo IV sold more than 10 million copies and broke several company records during its second-quarter financial results. Activision Blizzard reported net bookings growth of 50% year-over-year in the second quarter. The company is in the process of being acquired by Microsoft Corp (NASDAQ:MSFT). Musk's love of video games could play into the inclusion of Tesla Arcade, a platform that allows the playing of video games inside Tesla Inc (NASDAQ:TSLA) vehicles.

Portfolio Pulse from Chris Katje

August 07, 2023 | 9:34 pm

RNG

RingCentral, Inc. (NYSE:RNG) has announced the expansion of its AI platform, RingSense, across its portfolio. The new RingSense for Phone uses generative AI to turn voice conversation data into insights for enhancing productivity and improving business outcomes. It offers features like live transcriptions, call summaries, insights, and conversation sentiment analysis. RingSense for Phone is currently in beta and will be generally available later this year. RingCentral has also enhanced its RingSense for Sales, introduced in March 2023, with 10 new integrations with third-party applications and features like deal scoring and AI coaching.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 9:05 pm

CHGG

Chegg, Inc. (NYSE:CHGG) shares are trading higher after the company's Q2 earnings report. The company reported earnings of 28 cents per share, in line with analyst consensus, and sales of $182.90 million, beating the analyst consensus of $176.19 million. However, both figures represent a decrease from the same period last year. Subscription Services revenues and subscribers also decreased year-over-year. The company launched the beta version of its initial generative AI experience in May and received positive feedback.

Portfolio Pulse from Ryan Gustafson

August 07, 2023 | 9:04 pm

LMT

Lockheed Martin has successfully validated designs for all elements of the nation's Next Generation Interceptor (NGI) with the U.S. Missile Defense Agency. The company demonstrated it has achieved design maturity and reduced risk for critical technologies. The NGI program is on track for its next major review, the All Up Round PDR. The first Lockheed Martin NGI is forecast for delivery as early as FY2027.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:49 pm

MYGN

Myriad Genetics, Inc. (NASDAQ:MYGN) has announced enhancements to the GeneSight Psychotropic test, a pharmacogenomic test for mental health medications. The GeneSight report will now include information on how a patient's smoking status may impact their body's metabolism of certain medications. This update is based on a comprehensive analysis of peer-reviewed literature and is available immediately for prescribing clinicians.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 8:47 pm

XAIR

Beyond Air, Inc. (NASDAQ:XAIR) announced the presentation of data supporting the ongoing preclinical development of selective neuronal nitric oxide synthase (nNOS) inhibitors for the treatment of Autism Spectrum Disorder (ASD). The data, to be presented at the 2023 International Society of Neurochemistry and the European Society of Neurochemistry meeting in Portugal, shows that inhibition of nitric oxide (NO) production may reverse ASD phenotypes. The company plans to advance its selective nNOS inhibitors into a first-in-human study in 2025.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:45 pm

CRDF

PFE

Cardiff Oncology (NASDAQ:CRDF) has announced plans to advance its lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer Ignite. The company's cash position on June 30, 2023, was $89.4 million, sufficient to fund operations into 2025 and through interim topline results from the mCRC trial. The company estimates that there are 48,000 new patients in the U.S. annually in the first-line RAS-mutated mCRC setting for whom there are no ongoing clinical trials and no new treatments approved in the past 20 years.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:41 pm

BW

Babcock & Wilcox (B&W) has agreed to sell carbon-negative hydrogen and CO2 produced from biomass at its Louisiana plant to General Hydrogen Corp., a CGI Gases subsidiary. The hydrogen will be produced using B&W's BrightLoop technology, with production expected to start in mid-2026. General Hydrogen will purchase and transport up to 15 tons of hydrogen per day, while CGI Gases will purchase and transport the captured CO2. The deal also represents a geographic expansion for General Hydrogen Corp. and CGI Gases.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:36 pm